Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sirenko Maria, Lee Soobeom, Sun Zhengxi, Chaligne Ronan, Loghavi Sanam, Asimomitis Georgios, Brierley Charlotte K, Bernard Elsa, Cai Sheng F, Myers Robert M, Nadorp Bettina, Sango Junya, Lallo Morgan, Levine Max F, Domenico Dylan, Arango Ossa Juan E, Medina-Martinez Juan S, Menghrajani Kamal, Lasry Audrey, Mims Alice S, Desai Helee, Laganson Andrea, Famulare Chris, Patel Minal, Lozanski Gerard, Bolton Kelly L, Viny Aaron D, Roshal Mikhail, Levine Ross L, Papapetrou Eirini P, Stein Eytan M, Landau Dan A, Eisfeld Ann-Kathrin, Aifantis Iannis, Papaemmanuil Elli
Аннотация
Isocitrate dehydrogenase 1/2 (IDH) mutations are early initiating events in acute myeloid leukemia (AML). The complex clonal architecture and cellular heterogeneity in IDH-mutant AML underlies the heterogeneous clinical presentation and outcomes. Integrating single-cell genotyping and transcriptomics, we demonstrate a stem-like and inflammatory phenotype of IDH-mutant AML and identify clone-specific programs associated with NPM1, NRAS, and SRSF2 co-mutations. Furthermore, these clones had distinct responses to treatment with combination IDH inhibitors and chemotherapy, including elimination, reconstitution of myeloid differentiation, or retention within progenitor populations. At relapse after IDH inhibitor monotherapy, we identify upregulated stemness, inflammation, mitochondrial metabolism, and anti-apoptotic factors, as well as downregulated major histocompatibility complex (MHC) class II antigen presentation. At the pre-leukemic stage, we observe upregulation of IDH2-associated pathways, including inflammation. We deliver a detailed phenotyping of IDH-mutant AML and a framework for dissecting contributions of recurrently mutated genes in AML at diagnosis and following therapy, with implications for precision medicine.